Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis

Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis

Bibliographic Details
Main Authors:	Efstathios Kastritis, Evangelos Terpos, Aimilia Sklirou, Foteini Theodorakakou, Despina Fotiou, Eleni-Dimitra Papanagnou, Tina Bagratuni, Nikolaos Kanellias, Maria Gavriatopoulou, Ioannis P. Trougakos, Meletios A. Dimopoulos
Format:	Article
Language:	English
Published:	Wiley 2021-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000614

Similar Items

Future Developments in the Treatment of AL Amyloidosis
by: Foteini Theodorakakou, et al.
Published: (2022-02-01)

Biomarkers in AL Amyloidosis
by: Despina Fotiou, et al.
Published: (2021-10-01)

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
by: Despina Fotiou, et al.
Published: (2020-08-01)

Prevalence of MGCS Among Patients With Monoclonal Gammopathies
by: Foteini Theodorakakou, et al.
Published: (2023-06-01)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
by: Maria Gavriatopoulou, et al.
Published: (2020-06-01)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
by: Evangelos Terpos, et al.
Published: (2021-10-01)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2022-08-01)

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
by: Tina Bagratuni, et al.
Published: (2020-10-01)

B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Evangelos Terpos, et al.
Published: (2022-04-01)

P834: MULTIPARAMETRIC FLOW CYTOMETRY FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES
by: Ioannis Kostopoulos, et al.
Published: (2023-08-01)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-08-01)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-07-01)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
by: Vassiliki Spiliopoulou, et al.
Published: (2023-03-01)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
by: Evangelos Terpos, et al.
Published: (2021-07-01)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
by: Evangelos Terpos, et al.
Published: (2021-07-01)

Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
by: Efstathios Kastritis, et al.
Published: (2023-11-01)

Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity
by: Ioannis V. Kostopoulos, et al.
Published: (2024-02-01)

Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients
by: Nikolaos Kanellias, et al.
Published: (2022-05-01)

Cardiopulmonary Exercise Physiology in AL Amyloidosis Patients with Cardiac Involvement and Its Association with Cardiac Imaging Parameters
by: Alexandros Briasoulis, et al.
Published: (2022-09-01)

PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
by: Ioannis Kostopoulos, et al.
Published: (2023-08-01)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-09-01)

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
by: Panagiotis Malandrakis, et al.
Published: (2023-08-01)

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
by: Despina Fotiou, et al.
Published: (2022-12-01)

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
by: Evangelos Terpos, et al.
Published: (2021-09-01)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2022-07-01)

P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
by: Evangelos Terpos, et al.
Published: (2023-08-01)

P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY
by: Evangelos Terpos, et al.
Published: (2023-08-01)

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
by: Evangelos Terpos, et al.
Published: (2022-01-01)

P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING
by: Maria Papatsirou, et al.
Published: (2023-08-01)

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
by: Evangelos Terpos, et al.
Published: (2021-10-01)

Monoclonal Gammopathy of Thrombotic Significance
by: Vasiliki Gkalea, et al.
Published: (2023-01-01)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
by: Evangelos Terpos, et al.
Published: (2020-10-01)

Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study
by: Christina Zirou, et al.
Published: (2023-11-01)

Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin
by: Panagiotis Efentakis, et al.
Published: (2021-10-01)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
by: Efstathios Kastritis, et al.
Published: (2023-08-01)

De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment
by: Despina Fotiou, et al.
Published: (2021-12-01)

Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response
by: Ioanna Dagla, et al.
Published: (2022-04-01)

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
by: Evangelos Terpos, et al.
Published: (2019-12-01)

Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
by: Despina Fotiou, et al.
Published: (2020-01-01)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
by: Konstantinos Papadimitriou, et al.
Published: (2020-11-01)